1. Bittigau, P., et al., Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A, 2002. 99(23): p. 15089-94.
2. Painter, M.J., et al., Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med, 1999. 341(7): p. 485-9.
3. El-Dib, M. and J.S. Soul, The use of phenobarbital and other anti-seizure drugs in newborns. Semin Fetal Neonatal Med, 2017. 22(5): p. 321-327.
4. Barks, J.D., et al., Phenobarbital augments hypothermic neuroprotection. Pediatr Res, 2010. 67(5): p. 532-7.
5. Hall, R.T., F.K. Hall, and D.K. Daily, High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up. J Pediatr, 1998. 132(2): p. 345-8.
6. Smit, E., D. Odd, and A. Whitelaw, Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants. Cochrane Database Syst Rev, 2013(8): p. CD001691.
7. Kodama, S. and M. Negishi, Phenobarbital confers its diverse effects by activating the orphan nuclear receptor car. Drug Metab Rev, 2006. 38(1-2): p. 75-87.
8. Sueyoshi, T. and M. Negishi, Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol, 2001. 41: p. 123-43.
9. Tien, E.S. and M. Negishi, Nuclear receptors CAR and PXR in the regulation of hepatic metabolism. Xenobiotica, 2006. 36(10-11): p. 1152-63.
10. Stiehl, A., M.M. Thaler, and W.H. Admirand, The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis. N Engl J Med, 1972. 286(16): p. 858-61.
11. Sugatani, J., et al., The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology, 2001. 33(5): p. 1232-8.
12. Majd, M., R.C. Reba, and R.P. Altman, Hepatobiliary scintigraphy with 99mTc-PIPIDA in the evaluation of neonatal jaundice. Pediatrics, 1981. 67(1): p. 140-5.
13. Kimura, A., et al., Neonatal Dubin-Johnson syndrome with severe cholestasis: effective phenobarbital therapy. Acta Paediatr Scand, 1991. 80(3): p. 381-5.
14. Merdler, C., et al., The effect of phenobarbital on patients with Dubin-Johnson syndrome. Digestion, 1976. 14(5-6): p. 394-9.
15. Paulusma, C.C., et al., A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology, 1997. 25(6): p. 1539-42.
16. Cies, J.J. and J.N. Giamalis, Treatment of cholestatic pruritus in children. Am J Health Syst Pharm, 2007. 64(11): p. 1157-62.
17. Gleghorn, E.E., et al., Phenobarbital does not prevent total parenteral nutrition-associated cholestasis in noninfected neonates. JPEN J Parenter Enteral Nutr, 1986. 10(3): p. 282-3.
18. Lewis, T., S. Kuye, and A. Sherman, Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit. BMC Pediatr, 2018. 18(1): p. 197.
19. Nemeth, A., S.A. Wikstrom, and B. Strandvik, Phenobarbital can aggravate a cholestatic bile acid pattern in infants with obstructive cholangiopathy. J Pediatr Gastroenterol Nutr, 1990. 10(3): p. 290-7.
20. Bell, R.L., et al., Total parenteral nutrition-related cholestasis in infants. JPEN J Parenter Enteral Nutr, 1986. 10(4): p. 356-9.
21. Steinbach, M., et al., Demographic and nutritional factors associated with prolonged cholestatic jaundice in the premature infant. J Perinatol, 2008. 28(2): p. 129-35.
22. Shen, X., et al., Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. Clin Res Hepatol Gastroenterol, 2021. 45(2): p. 101495.
23. Kluckow, M. and N. Evans, Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr, 1995. 127(5): p. 774-9.
24. McNamara, P.J. and A. Sehgal, Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed, 2007. 92(6): p. F424-7.
25. Orso, G., et al., Pediatric parenteral nutrition-associated liver disease and cholestasis: Novel advances in pathomechanisms-based prevention and treatment. Dig Liver Dis, 2016. 48(3): p. 215-22.
26. Parry, G., J. Tucker, and W. Tarnow-Mordi, CRIB II: an update of the clinical risk index for babies score. Lancet, 2003. 361(9371): p. 1789-91.
27. Mohi-ud-din, R. and J.H. Lewis, Drug- and chemical-induced cholestasis. Clin Liver Dis, 2004. 8(1): p. 95-132, vii.
28. Ghorani-Azam, A., et al., Acute phenobarbital poisoning for the management of seizures in new-borns and children; A systematic literature review. CNS Neurol Disord Drug Targets, 2020.
29. Roberts, E.A., et al., Phenobarbital hepatotoxicity in an 8-month-old infant. J Hepatol, 1990. 10(2): p. 235-9.
30. Mockli, G., et al., Massive hepatic necrosis in a child after administration of phenobarbital. Am J Gastroenterol, 1989. 84(7): p. 820-2.
31. Bellu, R., K. de Waal, and R. Zanini, Opioids for neonates receiving mechanical ventilation: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed, 2010. 95(4): p. F241-51.
32. Forcelli, P.A., et al., Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia, 2011. 52(12): p. e207-11.
33. Kaushal, S., et al., Anticonvulsant drug-induced cell death in the developing white matter of the rodent brain. Epilepsia, 2016. 57(5): p. 727-34.
34. Reinisch, J.M., et al., In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA, 1995. 274(19): p. 1518-25.
35. Yaffe, S.J. and L.D. Dorn, Effects of prenatal treatment with phenobarbital. Dev Pharmacol Ther, 1990. 15(3-4): p. 215-23.
36. Gutherz, S.B., et al., Brief postnatal exposure to phenobarbital impairs passive avoidance learning and sensorimotor gating in rats. Epilepsy Behav, 2014. 37: p. 265-9.
37. Kamitaki, B.K., et al., Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS). Epilepsy Behav, 2021. 117: p. 107832.
38. Santos, N.A., et al., Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver. Toxicol In Vitro, 2008. 22(5): p. 1143-52.
39. Santos, N.A., et al., Involvement of oxidative stress in the hepatotoxicity induced by aromatic antiepileptic drugs. Toxicol In Vitro, 2008. 22(8): p. 1820-4.
40. Yamaguchi, T., et al., The effects on the endocrine system under hepatotoxicity induction by phenobarbital and di(2-ethylhexyl)phthalate in intact juvenile male rats. J Toxicol Sci, 2019. 44(7): p. 459-469.
41. Pitlick, W., M. Painter, and C. Pippenger, Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther, 1978. 23(3): p. 346-50.
42. Pacifici, G.M., Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. Curr Pediatr Rev, 2016. 12(1): p. 48-54.